A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.
The results of this study are not yet available.
Your participation could last up to 28 weeks and include 10 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a confirmed diagnosis of Sjögren's Syndrome
Participant is seropositive for auto-antibodies associated with SS (anti-SSA or anti-SSB) at screening, or documented within 6 months prior to screening
Participant must not be currently enrolled in a clinical trial involving an investigational product or off-label use of a drug
Participant must not have taken Etanercept, adalimumab, or anakinra <4 weeks before entering the study
Participant must not have taken Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks before entering the study
Participant must not have taken Rituximab, belimumab or other leukocyte depleting agent <12 months before entering the study